Insulin Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017-2021 and Forecast 2022-2028

$ PRICE - $ 3,000.00$ 8,900.00

Insulin Market: By Product Type (Rapid Acting Insulin, Short Acting Insulin, Intermediate Acting Insulin, Long Acting Insulin, Ultra Long Acting Insulin) Diabetes Type (Type 1 diabetes, Type 2 diabetes) End User (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Others) and Geography 

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Category:

Report

Description

Insulin Market size is valued at USD 42.5 billion in 2021 and is expected to grow at a CAGR of 8.2% during the forecast period from 2022 to 2028. The human pancreas releases the hormone insulin, which controls the body’s metabolism of lipids, carbohydrates, proteins, and blood glucose or sugar levels. Various strengths of insulin are accessible; the most popular is U-100, which is used as a enhancement to diet and exercise to progress glycemic control in both adults and children. The global market provides a detailed overview of the Insulin market, and that can be segmented by product type, by Diabetes Type, and By End User. By product type, the Insulin market has been segmented into Ultra-short acting insulin, Short-acting insulin, Intermediate-acting insulin, Long-acting insulin, and Premixed insulin. The long-acting insulin segment is likely to be the largest and fastest-growing segment in terms of product type. The rise of this segment is mainly due to the protection of patents and high demand due to lasting effects. Factors such as the protection of patents and high demand due to the lasting impacts are expected to drive the segment. Levemir, Toujeo, Insulatard, Xultophy, , and Lantus are among the main products in the product type segment. Based on Diabetes Type, the Insulin market is segmented into Type 1 diabetes and Type 2 diabetes types. Among these, the type 1 diabetes mellitus segment is expected to have the fastest-growing market during the forecast period 2022-2028. The major factor for the rise of this segment is the high insulin dependence of the patients. It is a more serious condition compared to type 2 diabetes and it has a high prevalence rate. Based on the End User, the Insulin market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The retail pharmacy segment is expected to have a significant share in 2021. The rise of this segment is mainly because of the growing burden of disease, the possibility of home care patients, and numerous discounts provided by retail pharmacies.

Key Developments:

In February 2022, Biocon acquired Viatris to access its biosimilar products.

In July 2021, a glargine biosimilar, Semglee, produced by Mylan Pharmaceuticals Inc. received FDA approval.

Insulin Market

MARKET SUMMARY
-
8.2% CAGR
  • Study Period– 2022-2028
  • Base Year– 2021
  • CAGR– 8.2%
  • Largest Market– North America
  • Fastest Growing Market– Asia-Pacific

Insulin Market

  • The insulin market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • The insulin market is segmented based on product type, diabetes type, end user. and geography.
Key Players
  • Eli Lilly and Co.
  • Merck & Co, Inc.
  • Novo Nordisk A/S
  • Sanofi
  • GlaxoSmithKline Plc.
Insulin Market Drivers

The increasing number of diabetics patient and growing demand for insulin are anticipated to propel the market growth over the forecast years. Moreover, the increasing patient population with diabetes and a rise in the number of research and development activities relating to insulin delivery systems are burgeoning the market growth over the forecast years.


North-America Got Significant Share

Insulin Market

North America market is expected to witness the highest market share during the forecast period.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The Insulin market provides granular level information about the market size, regional market share, historic market (2017-2021) and forecast (2022-2028)
  • The Insulin market covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The Insulin market outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The Insulin market tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The Insulin market provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Insulin Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The insulin market is projected to expand at a CAGR of 8.2% during the forecast period

Novo Nordisk, Sanofi-Aventis, Eli Lilly, Biocon, Bioton, Wockhardt, Julphar, MannKind Corporation, Wanbang Biopharmaceuticals, Incepta Pharma Ltd, Popular Pharma Ltd

North America is the fastest-growing region for insulin market


Report

Table Of Content

1. Executive Summary
2. Global Insulin Market Introduction
2.1. Global Insulin Market – Taxonomy
2.2. Global Insulin Market –Definitions
2.2.1. Product Type
2.2.2. Route of Administration
2.2.3. Distribution Channel
2.2.4. Region
3. Global Insulin  Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. New Product Launches
3.6. Collaborations, Acquisitions and Mergers
3.7. Global Insulin  Market – Competition Landscape
3.8. Global Insulin  Market Dynamic Factors – Impact Analysis
4. Global Insulin  Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Insulin  Market, By Product Type, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1. Rapid Acting Insulin
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Short Acting Insulin
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Intermediate Acting Insulin
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Long Acting Insulin
5.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Ultra Long Acting Insulin
5.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
6. Global Insulin Market Forecast, By Route of Administration Type, 2017 – 2021 and Forecast, 2022 – 2028
6.1. Intravenous
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Inhalational
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
7. Global Insulin Market Forecast, By Distribution Channel, 2017 – 2021 and Forecast, 2022 – 2028
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Others
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. Global Insulin Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.1. North America
8.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Insulin Market – Opportunity Analysis Index, By Product Type, By Route of Administration Type, By Distribution Channel, and Region, 2022 – 2028
9. North America Insulin Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Rapid Acting Insulin
9.1.2. Short Acting Insulin
9.1.3. Intermediate Acting Insulin
9.1.4. Long Acting Insulin
9.1.5. Ultra Long Acting Insulin
9.2. Route of Administration Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Intravenous
9.2.2. Inhalational
9.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Retail Pharmacies
9.3.2. Hospital Pharmacies
9.3.3. Others
9.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. U.S.
9.4.2. Canada
9.5. North America Insulin  Market – Opportunity Analysis Index, By Product Type, By Route of Administration Type, By Distribution Channel, and Country, 2022 – 2028
9.6. North America Insulin  Market Dynamics – Trends
10. Europe Insulin  Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Rapid Acting Insulin
10.1.2. Short Acting Insulin
10.1.3. Intermediate Acting Insulin
10.1.4. Long Acting Insulin
10.1.5. Ultra Long Acting Insulin
10.2. Route of Administration Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Intravenous
10.2.2. Inhalational
10.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Retail Pharmacies
10.3.2. Hospital Pharmacies
10.3.3. Others
10.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Poland
10.4.8. Rest of Europe
10.5. Europe Insulin Market – Opportunity Analysis Index, By Product Type, By Route of Administration Type, By Distribution Channel, And By Country, 2022 – 2028
10.6. Europe Insulin  Market Dynamics – Trends
11. Asia-Pacific Insulin  Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
11.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Rapid Acting Insulin
11.1.2. Short Acting Insulin
11.1.3. Intermediate Acting Insulin
11.1.4. Long Acting Insulin
11.1.5. Ultra Long Acting Insulin
11.2. Route of Administration Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Intravenous
11.2.2. Inhalational
11.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Retail Pharmacies
11.3.2. Hospital Pharmacies
11.3.3. Others
11.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Insulin  Market – Opportunity Analysis Index, By Product Type, By Route of Administration Type, By Distribution Channel, And By Country, 2022 – 2028
11.6. Asia-Pacific Insulin  Market Dynamics – Trends
12. Latin America Insulin  Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
12.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Rapid Acting Insulin
12.1.2. Short Acting Insulin
12.1.3. Intermediate Acting Insulin
12.1.4. Long Acting Insulin
12.1.5. Ultra Long Acting Insulin
12.2. Route of Administration Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Intravenous
12.2.2. Inhalational
12.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Retail Pharmacies
12.3.2. Hospital Pharmacies
12.3.3. Others
12.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Insulin  Market – Opportunity Analysis Index, By Product Type, By Route of Administration Type, By Distribution Channel, And By Country, 2022 – 2028
12.6. Latin America Insulin  Market Dynamics – Trends
13. Middle East and Africa Insulin  Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
13.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Rapid Acting Insulin
13.1.2. Short Acting Insulin
13.1.3. Intermediate Acting Insulin
13.1.4. Long Acting Insulin
13.1.5. Ultra Long Acting Insulin
13.2. Route of Administration Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Intravenous
13.2.2. Inhalational
13.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Retail Pharmacies
13.3.2. Hospital Pharmacies
13.3.3. Others
13.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Insulin  Market – Opportunity Analysis Index, By Product Type, By Route of Administration Type, By Distribution Channel, And By Country, 2022 – 2028
13.6. MEA Insulin  Market Dynamics – Trends
14. Competition Landscape
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Novo Nordisk
14.2.2. Sanofi-Aventis
14.2.3. Eli Lilly
14.2.4. Biocon
14.2.5. Bioton
14.2.6. Wockhardt
14.2.7. Julphar
14.2.8. MannKind Corporation
14.2.9. Wanbang Biopharmaceuticals
14.2.10. Incepta Pharma Ltd
14.2.11. Popular Pharma Ltd
15. Research Methodology
16. Key Assumptions and Acronyms


Report

Company Profile

  • Novo Nordisk
  • Sanofi-Aventis
  • Eli Lilly
  • Biocon
  • Bioton
  • Wockhardt
  • Julphar
  • MannKind Corporation
  • Wanbang Biopharmaceuticals
  • Incepta Pharma Ltd
  • Popular Pharma Ltd

Description

Insulin Market size is valued at USD 42.5 billion in 2021 and is expected to grow at a CAGR of 8.2% during the forecast period from 2022 to 2028. The human pancreas releases the hormone insulin, which controls the body’s metabolism of lipids, carbohydrates, proteins, and blood glucose or sugar levels. Various strengths of insulin are accessible; the most popular is U-100, which is used as a enhancement to diet and exercise to progress glycemic control in both adults and children. The global market provides a detailed overview of the Insulin market, and that can be segmented by product type, by Diabetes Type, and By End User. By product type, the Insulin market has been segmented into Ultra-short acting insulin, Short-acting insulin, Intermediate-acting insulin, Long-acting insulin, and Premixed insulin. The long-acting insulin segment is likely to be the largest and fastest-growing segment in terms of product type. The rise of this segment is mainly due to the protection of patents and high demand due to lasting effects. Factors such as the protection of patents and high demand due to the lasting impacts are expected to drive the segment. Levemir, Toujeo, Insulatard, Xultophy, , and Lantus are among the main products in the product type segment. Based on Diabetes Type, the Insulin market is segmented into Type 1 diabetes and Type 2 diabetes types. Among these, the type 1 diabetes mellitus segment is expected to have the fastest-growing market during the forecast period 2022-2028. The major factor for the rise of this segment is the high insulin dependence of the patients. It is a more serious condition compared to type 2 diabetes and it has a high prevalence rate. Based on the End User, the Insulin market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The retail pharmacy segment is expected to have a significant share in 2021. The rise of this segment is mainly because of the growing burden of disease, the possibility of home care patients, and numerous discounts provided by retail pharmacies.

Key Developments:

In February 2022, Biocon acquired Viatris to access its biosimilar products.

In July 2021, a glargine biosimilar, Semglee, produced by Mylan Pharmaceuticals Inc. received FDA approval.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX